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ABSTRACT
Objective: One-year adjuvant trastuzumab therapy increases disease-
free and overall survival in the adjuvant treatment of early HER2-
positive breast cancer. This study aims to assess the long-term
cost-effectiveness of adjuvant trastuzumab treatment in Beijing, Shang-
hai, and Guangzhou.
Methods: A Markov health-state transition model was constructed to
simulate the natural development of breast cancer based on HERceptin
Adjuvant (HERA) trial, estimate costs and disease progression over a
lifetime perspective with annual transition cycles, and evaluate the cost-
effectiveness of 1-year adjuvant trastuzumab treatment group compared
with the standard adjuvant chemotherapy. From the perspective of a
China health insurance system, cost was calculated based on a survey from
clinical expert panels.
Results: On the basis of HERA data, the model results showed that the
utilization of adjuvant trastuzumab treatment in early breast cancer can
prolong 2.87 life years, compared with the standard chemotherapy group.
The incremental cost for an additional life-year gained (LYG)wasUS$7564,
US$7933, and US$7929 in Beijing, Shanghai, andGuangzhou, respectively.
If measured by quality-adjusted life-year, the incremental cost-effectiveness
ratio was US$7676, US$8049, and US$8046, respectively.
Conclusion: The results suggest that the 1-year adjuvant trastuzumab
treatment is cost-effective. Both clinical and economic beneﬁts were supe-
rior for the 1-year adjuvant trastuzumab treatment group compared with
the standard adjuvant chemotherapy group.
Keywords: adjuvant treatment, breast cancer, cost-effectiveness,
trastuzumab.
Introduction
According to the National Cancer Deaths Retrospective Survey,
the mortality rate of breast cancer was 3.37 and 3.53 per
100,000 females in 1973 to 1975 and 1990 to 1992, respectively,
and it increased to 5.90 per 100,000 females in 2004 to 2005 in
China [1]. There was an uptrend either in the morbidity and
mortality, or in absolute number, during 2000 and 2005. The
number of new cases has increased by 38.5% and death toll rose
by 37.1% [2]. Breast cancer has already become one of the most
common cancers for the women in Beijing, Shanghai, and other
developed regions [3]. The deaths due to breast cancer were
estimated as 37,595 per year in China [4]. Reducing the deaths
caused by breast cancer is one of the most important issues for
Chinese women’s public health.
Oncogene erb B-2, called HER-2/neu, is an important mol-
ecule marker and curing target of breast cancer because of close
correlation between its abnormal ampliﬁcation and expression
and the occurrence and progression of breast cancer [5]. Trastu-
zumab (Herceptin), a recombinant, humanized, monoclonal anti-
body targeting HER2 is well established as an effective treatment
for HER2-positive breast cancer. Many studies had proven the
obvious effects of trastuzumab in treating metastatic breast
cancer. It was notable that trastuzumab signiﬁcantly reduced the
risks of cancer local recurrence and metastasis and can prolong
survival time of the patients [6–8].
Though the cost of adjuvant trastuzumab treatment is high,
the National Institute for Health and Clinical Excellence (NICE)
has recommended adjuvant trastuzumab treatment for HER2-
positive breast cancer patients [9,10]; and the evidence from
other countries showed that trastuzumab was of high cost-
effectiveness in adjuvant treatment for early breast cancer
[11,12], there is still no evidence of this kind in China. With its
high treatment cost, it is a concern whether trastuzumab is of
economic value for the patients. With the development of China’s
health insurance system, cost-effectiveness and outcomes evi-
dence tends to be vital for the policymaking to make a tradeoff
between limited ﬁnancial resources and equitable access, espe-
cially in urban China where there exists higher demand for high
quality health care. Therefore, this cost-effectiveness analysis is
designed to examine the economic value of adjuvant trastuzumab
therapy based on the HERceptin Adjuvant (HERA) trial to
support health insurance decision-making.
Materials and Methods
AMarkov health-state transition model was constructed to assess
the cost-effectiveness of 1-year adjuvant trastuzumab treatment
for women with HER2-positive early breast cancer. Two treat-
ment scenarios were examined: 1-year adjuvant trastuzumab
treatment after surgical therapy of early breast cancer and stan-
dard adjuvant chemotherapy (combination of docetaxel, doxoru-
bicin, and cyclophosphamide) after surgical therapy. Clinical data
and the treatment protocol were based on the results of the HERA
trial. Five key health states were identiﬁed in the progression of
breast cancer, including disease-free state (representing the health
state after the completion of surgery and chemotherapy, disease-
free state [DFS]), recurrence (local and contralateral recurrence),
metastasis, cardiac event, and death (see Fig. S1 at An Economic
Evaluation Of Adjuvant Trastuzumab Therapy In HER2-Positive
Early Breast Cancer Value in Health Supporting Information
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_WChen2.asp). The model was simulated from lifetime
perspective. The cycle length was 1 year and the maximum cycle
number was 45. For modeling purposes, it was assumed that each
patient can experience only one locoregional or contralateral
breast cancer recurrence. After a single year in the locoregional/
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contralateral recurrence state, the patients returned to the recur-
rence health state and remained there until they die or experience
metastasis.
Clinical Data
According to the HERA study, it was assumed that there were two
groups each having 100 50-year-old patients in the DFS after
surgery followed by adjuvant therapy. In the trastuzumab group,
all patients were treated with adjuvant trastuzumab for 1 year and
followed by standard chemotherapy. In the observation group, all
patients were treated with standard adjuvant chemotherapy. The
speciﬁc transition probabilities of disease progression for the two
groups were retrieved from the HERA study and literature (see
Table S1 at An Economic Evaluation Of Adjuvant Trastuzumab
Therapy In HER2-Positive Early Breast Cancer Value in Health
Supporting Information at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH12s3_WChen2.asp) [9,13].
The impact of trastuzumab on disease progression is esti-
mated by applying the hazard ratio (HR) observed in the HERA
study, i.e., the unadjusted HR for the risk of recurrence in the
trastuzumab group, as compared with the comparator group,
was 0.54 (95% conﬁdence interval, 0.43 to 0.67) [9]. We
assumed a constant yearly risk for local and distant recurrences
during the ﬁrst 5 years after treatment before decreasing in a
stepwise function at 5 and 10 years, i.e., the adjustment of
baseline risk due to the time elapsed because surgery without a
recurrence is divided into three different categories: 0–5 years,
6–10 years, over 11 years. This adjustment of baseline risks takes
into account that the probability to develop a recurrence is
reduced among long-term survivors who have not experienced
any recurrences. The clinical beneﬁt of trastuzumab was assumed
to last for the ﬁrst 5 years [13]. Thereafter, the relative risk for
recurrent and metastatic disease in the trastuzumab group was
assumed to be the same as in the observation group. Population-
based utilities associated with different health states were derived
from published literature (see Table S2 at An Economic Evalua-
tion Of Adjuvant Trastuzumab Therapy In HER2-Positive Early
Breast Cancer Value in Health Supporting Information at: http://
www.ispor.org/Publications/value/ViHsupplementary/ViH12s3_
WChen2.asp) [13–17]. The age-speciﬁc death rates for DFS and
recurrence states were assumed to be the same as that of the
whole population, taken from the China National Population
Statistics [18].
Cost Data
The evaluation was considered from the perspective of
China’s health insurance system and includes only direct medical
expenditures.
The loading dose of trastuzumab in the model was 4 mg per
kilogram weight and 2 mg per kilogram weekly. The average
weight of patients with breast cancer was 58 kg in the model and
assumed to be the same as that of general population [19].
To estimate the resource utilization and related costs, a survey
of clinical expert panels was conducted with a structured ques-
tionnaire. The survey questionnaire was designed to understand
the detailed treatment choices in the DFS, local and contralateral
recurrence, advanced breast cancer, and cardiac events. In total,
28 famous clinical experts in breast cancer specialty chosen in the
whole country have been investigated to inquire the proportion
of the average follow-up patients who take outpatient visit and
hospitalization and the frequency of medical care utilization
including examination, lab tests, and all kinds of treatments
(surgery, hormonal therapy, chemotherapy, radiotherapy, special
interventions). All clinical experts were required to give the
second estimate based on the feedback of the average of every
item derived from the ﬁrst round survey. The average of every
item based on the second round survey was calculated and
employed to measure the annual medical expenditure burden
under different health states according to the fee schedule of
medical services and pharmaceuticals related in Beijing, Shang-
hai, and Guangzhou cities as representatives of urban China.
A discounting rate at 3% was used to discount medical
expenditures that happened at different years.
Sensitivity Analysis
We conducted univariate sensitivity analyses with Monte-Carlo
simulation method to understand the key drivers and general
sensitivity of the model. The following variables were assessed:
discounting rate of medical expenditure, discount rate of life
years, the probabilities of DFS progressed to recurrence and
metastisis, the price of trastuzumab, and the cost of ﬁrst year in
recurrence and metastatic state.
Results
Annual Medical Expenditure in Different Health States
The annual medical expenditure except trastuzumab cost was
assumed to be the same in different health states for trastuzumab
and observation group (see Table S3 at An Economic Evaluation
Of Adjuvant Trastuzumab Therapy In HER2-Positive Early
Breast Cancer Value in Health Supporting Information at: http://
www.ispor.org/Publications/value/ViHsupplementary/ViH12s3_
WChen2.asp). The trastuzumab cost was calculated according to
an average patient with the weight of 58 kg and reached
US$54,043 for 1-year treatment. The results showed that there
was higher medical expenditure burden in ﬁrst year in local and
contralateral recurrence state and metastatic state.
Cost-Effectiveness Analysis
The total life years obtained for the treatment with trastuzumab
are 18.17 years and 15.30 years for the treatment without tras-
tuzumab, meaning the incremental life years of 2.87 years for the
patients treated with trastuzumab. According to the measure-
ment of quality-adjusted life-years (QALY), the incremental
QALY of 2.83 years are generated with trastuzumab treatment
(see Table S4 at An Economic Evaluation Of Adjuvant Trastu-
zumab Therapy In HER2-Positive Early Breast Cancer Value
in Health Supporting Information at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_WChen2.asp).
The discounted lifetime medical expenditure for trastuzumab
treatment reached US$83,960 to US$89,800, increasing by
US$21,700 to US$22,760 compared with that without trastu-
zumab treatment.
The results showed that the incremental cost-effectiveness
ratio (ICER) for trastuzumab treatment ranged from US$7564 to
US$7933 per LYG. If measured by QALY, the ICER was esti-
mated to be US$7676 to US$8049 per QALY gained.
Sensitivity Analysis
The cost-effectiveness of trastuzumab depends on some key
parameters, including the discounting rate of medical expendi-
ture and life-year, the probabilities of DFS progressed to recur-
rence and metastisis, the price of trastuzumab, and the cost of
ﬁrst year in recurrence and metastatic state. Figure S2 (found at
An Economic Evaluation Of Adjuvant Trastuzumab Therapy
In HER2-Positive Early Breast Cancer Value in Health Support-
ing Information at: http://www.ispor.org/Publications/value/
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ViHsupplementary/ViH12s3_WChen2.asp) presents the various
incremental costs per QALY gained when these parameters are
changed. The results highlight the sensitivity of the model to
these parameters but also demonstrate that they remain cost-
effective even with the most conservative assumptions as showed
by the cost-effectiveness acceptability curve for Beijing case (see
Fig. S3 at An Economic Evaluation Of Adjuvant Trastuzumab
Therapy In HER2-Positive Early Breast Cancer Value in Health
Supporting Information at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH12s3_WChen2.asp).
Discussion
Adjuvant trastuzumab has been proven to be a cost-effective
regimen for HER-2 positive early breast cancer in many counties.
In Switzerland, Dedes et al. found that adjuvant trastuzumab is a
cost-effective regimen based on the clinical data from HERA
trial, and ICER was about €17,000 to €38,000 per LYG [20]. In
UK, a cost-effectiveness analysis submitted to NICE presented
that the ICER of adjuvant trastuzumab treatment was £2396 and
NICE has recommended adjuvant trastuzumab treatment for
HER2-positive breast cancer patients [10,21]. In Japan, a cost-
effectiveness model based on HERA trial showed that the ICER
of adjuvant trastuzumab was JPY2,600,000 (€17,000) and con-
cluded that adjuvant trastuzumab treatment was superior to the
comparator [22].
Our model yielded a similar result as mentioned previously. In
this comparison of observation after standard adjuvant chemo-
therapy, 1-year adjuvant trastuzumab treatment yielded an ICER
of US$7564, US$7933, and US$7929 in Beijing, Shanghai, and
Guangzhou, respectively. If measured by QALY, the ICER was
US$7676, US$8049, and US$8046, respectively. According to
the deﬁnition of WHO cost-effectiveness threshold [23], the adju-
vant trastuzumab treatment for HER2-positive early breast
cancer in developed urban China is cost-effective using gross
domestic product (GDP) per capita (2006) as threshold [24].
Nevertheless, the major limitation of our analysis is the
absence of long-term clinical evidence with adjuvant trastu-
zumab, leading to uncertainty about efﬁcacy and toxicity of the
alternative approaches to care over the years. Our model is based
on the clinical data of one 1-year randomized clinical trial. The
long-term clinical beneﬁt had to be estimated by modeling tech-
niques. More evidences on the effectiveness of adjuvant trastu-
zumab therapy are needed. Nevertheless, adjuvant trastuzumab
regimen has been approved in many countries based on this
short-term clinical data. The another limitation is that we used
UK utilities in the model conﬁrmed by Chinese clinical experts
through Delphi method, because in China there are no health-
related quality of life data for breast cancer patients applied to
our analysis.
Based on the HERA trial and our economic analysis, we can
conclude that 1-year adjuvant trastuzumab treatment is cost-
effective compared with observation in a long-term perspective.
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